Armistice Capital »

Prothena shares owned by Armistice Capital

Quarter-by-quarter ownership of Prothena (PRTA) shares owned by Armistice Capital from 13F filings

Historical chart of Armistice Capital investment in Prothena

Tip: Access up to 7 years of quarterly data

All positions including Prothena held by Armistice Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Prothena by Armistice Capital

Quarter filed Position value Share count Share price at filing
2024-03-31 $27M 1.1M 24.77

More positions owned by Armistice Capital

Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Ishares Tr Russell 2000 Etf Put Option (IWM)
Ptc Therapeutics I (PTCT)
Cytokinetics Com New (CYTK)
Neurocrine Biosciences (NBIX)
Incyte Corporation (INCY)
Supernus Pharmaceuticals (SUPN)
Argenx Se Sponsored Adr (ARGX)
Deciphera Pharmaceuticals (DCPH)
Agios Pharmaceuticals (AGIO)
Immunovant (IMVT)
Sanofi Sponsored Adr (SNY)
Aurinia Pharmaceuticals (AUPH)
Dentsply Sirona (XRAY)
Travere Therapeutics (TVTX)

View all positions for Armistice Capital

Top funds holding Prothena

EcoR1 Capital
FMR
T. Rowe Price Associates
BlackRock
Wellington Management Company
Palo Alto Investors
Henderson Group
Vanguard Group
Armistice Capital
Artal Group
Geode Capital Management
Dimensional Fund Advisors
Boxer Capital
Morgan Stanley
Rock Springs Capital Management

View all funds holding Prothena